The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 07, 2018

Filed:

Nov. 30, 2016
Applicant:

The Industry & Academic Cooperation IN Chungnam National University (Iac), Daejeon, KR;

Inventors:

Yeon Soo Kim, Daejeon, KR;

Moonkyung Kang, Daejeon, KR;

Min Jeong Baek, Daejeon, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 63/00 (2006.01); A61K 48/00 (2006.01); A61K 31/495 (2006.01); A61K 31/513 (2006.01); A61K 38/50 (2006.01); A61K 35/768 (2015.01); C12N 9/78 (2006.01); C12N 9/12 (2006.01); C12N 15/86 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0058 (2013.01); C12N 7/00 (2013.01); C12N 9/1211 (2013.01); C12N 9/78 (2013.01); C12N 15/86 (2013.01); C12Y 305/04001 (2013.01); C12N 2740/10043 (2013.01); C12N 2740/10052 (2013.01); C12N 2740/13022 (2013.01); C12N 2740/13043 (2013.01);
Abstract

The present invention relates to a replication retrovirus vector system comprising thymidine kinase (HSV-TK) gene and cytosine deaminase (CD) gene which make gene transfer to cancer cell tissue for the efficient treatment of cancer. Particularly, the HSV-TK/CD combined self-replicating retrovirus vector system of the present invention characteristically contains both HSV-TK and CD genes; has no worries about losing a therapeutic gene because recombination does not occur in this system during virus infection; and has an excellent stability, and also is able to induce cancer cell death by using the prodrug GCV or 5-FC and can apply a therapeutic gene or a prodrug thereof selectively to such cancer that shows resistance against cancer treatment using either TK or CD, so that this system of the invention can be advantageously used as a pharmaceutical composition for the treatment of cancer.


Find Patent Forward Citations

Loading…